4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

Cantor Fitzgerald initiated coverage of Q32 Bio with a rating of Overweight

H.C. Wainwright initiated coverage of Q32 Bio with a rating of Buy and set a new price target of $13.00

BMO Capital Markets downgraded Q32 Bio from Outperform to Market Perform and set a new price target of $3.00 from $22.00 previously

Piper Sandler downgraded Q32 Bio from Overweight to Neutral and set a new price target of $4.00 from $20.00 previously

Guggenheim downgraded Q32 Bio from Buy to Neutral

Wells Fargo downgraded Q32 Bio from Overweight to Equal Weight and set a new price target of $16.00 from $95.00 previously

Raymond James downgraded Q32 Bio from Strong Buy to Outperform and set a new price target of $22.00 from $90.00 previously

Leerink Partners downgraded Q32 Bio from Outperform to Market Perform and set a new price target of $9.00 from $68.00 previously

BMO Capital Markets initiated coverage of Q32 Bio with a rating of Outperform and set a new price target of $64.00

Raymond James initiated coverage of Q32 Bio with a rating of Strong Buy and set a new price target of $90.00

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)

S-3 - Q32 Bio Inc. (0001661998) (Filer)

8-K - Q32 Bio Inc. (0001661998) (Filer)

424B5 - Q32 Bio Inc. (0001661998) (Filer)

EFFECT - Q32 Bio Inc. (0001661998) (Filer)

424B5 - Q32 Bio Inc. (0001661998) (Filer)

8-K - Q32 Bio Inc. (0001661998) (Filer)

8-K - Q32 Bio Inc. (0001661998) (Filer)

SCHEDULE 13G/A - Q32 Bio Inc. (0001661998) (Subject)

S-3 - Q32 Bio Inc. (0001661998) (Filer)

WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-fu

WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Q32 Bio intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissio

-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis ---- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at Week 36 in the ITT analysis of all enrolled patients ---- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals ---- Bempikibart demonstrated a favorable PK, PD and ADA profile -- -- Data supports further development of bempikibart in alopecia areata; Company intends to advance a registration-directed program in the first half of 2027 ---- Q32

-- Conference call to be held Monday, July 13th at 8:00 a.m. E.T. --WALTHAM, Mass., July 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA on Monday, July 13, 2026. Following the announcement, Q32 Bio will host a conference call and webcast at 8:00 a.m. E.T. on Monday, July 13, 2026 to discuss the results.Conference CallQ32 Bio's live conference call an

WALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants for an aggregate of approximately $55 million.In this private placement, the Company has agreed to issue and sell to such institutional and accredited investors (i) 6,725,000 shares (the "Shares") of the Company's common stock, $0.0001 par

-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 ---- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) ---- Completed $10.5 million registered direct offering (RDO) ---- Cash and cash equivalents of $50.8 million as of March 31, 2026, combined with guaranteed near-term milestone payments from ADX-097 asset sale and proceeds from sales under at-the-market (ATM) program received after the end of the quarter, are expected to provide financial runway into 1H'2028 --WALTHAM, Mass., May 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innov

WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 ---- Completed $10.5 million registered direct offering (RDO) ---- Completed asset sale of Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics to further enable Company's strategic focus on advancing bempikibart for alopecia areata (AA) ---- Cash and cash equivalents of $48.3 million as of December 31, 2025, combined with gross proceeds from RDO and guaranteed near-term milestone payments from ADX-097 asset sale, expected to provide financial runway into Q4'27 --WALTHAM, Mass., March 10, 2026 /PRNew

The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targe

-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis ---- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at Week 36 in the ITT analysis of all enrolled patients ---- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals ---- Bempikibart demonstrated a favorable PK, PD and ADA profile -- -- Data supports further development of bempikibart in alopecia areata; Company intends to advance a registration-directed program in the first half of 2027 ---- Q32

-- Conference call to be held Monday, July 13th at 8:00 a.m. E.T. --WALTHAM, Mass., July 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA on Monday, July 13, 2026. Following the announcement, Q32 Bio will host a conference call and webcast at 8:00 a.m. E.T. on Monday, July 13, 2026 to discuss the results.Conference CallQ32 Bio's live conference call an

WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent

WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targe

-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --  -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both trials planned to start treating subjects in 2026 CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the establishment of its rare kidney disease pipeline. The pipeline is comprised of two core product candidates: A

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patients in Part A open-label extension (OLE) ongoing -- -- Cash and cash equivalents of $49.0 million as of September 30, 2025 expected to provide financial runway into 2027 -- WALTHAM, Mass., Nov. 13, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended September 30, 2025, and provided

-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.

WALTHAM, Mass., Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 3:45 p.m. E.T. on Thursday, September 4th at the 2025 Wells Fargo Healthcare Conference. A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event. About Q32 Bio Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of

-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Strengthened leadership team with appointment of Adrien Sipos, M.D., Ph.D., an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, as Interim Chief Medical Officer -- -- Cash and cash equivalents of $54.8 million as of June 30, 2025, which is now expected to provide financial runway into 2027 -- WALTHAM, Mass., Aug. 6, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflamm

SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

SC 13G - Q32 Bio Inc. (0001661998) (Subject)

SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)